Nirsevimab, a new monoclonal antibody treatment for respiratory syncytial virus, was 90% effective at preventing hospitalizations among infants this virus season, according to a March 7 CDC report.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
